A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection

• DOI: 10.1016/j.vaccine.2015.01.062
• Publication Date: 2015-02-07T13:48:29Z
• Authors: Estela Rodriguez-...; Marco Marradi; Ricardo Calderon-...; Elisabet Frande-C...; Soledad Penadés; Nikolai Petrovsky; Carmen Alvarez-Do...
• Keywords: Listeriolysin O

In the search for an effective vaccine against human pathogen, Listeria monocytogenes (Listeria), gold glyconanoparticles (GNP) loaded with a listeriolysin O peptide LLO91–99 (GNP-LLO) were used to immunise mice, initially using dendritic cell (DC) approach, but subsequently standard parenteral immunisation approach. To enhance immunogenicity novel polysaccharide adjuvant based on delta inulin (Advax™) was also co-formulated GNP vaccine. Confirming previous results, DC in vitro GNP-LLO provided better protection listeriosis than free LLO peptide. The of vaccines further increased by addition Advax™ adjuvant. However, as are expensive and impracticable prophylactic use, we next asked whether same antigen could be directly target vivo. Immunisation mice plus induced LLO-specific T-cell immunity challenge. Protection correlated frequency splenic CD4+ CD8+ T cells, NK cells CD8α+ DC, Th1 cytokine production (IL-12, IFN-γ, TNF-α, MCP-1), post-challenge. Enhanced epitope recruitment post-challenge seen groups that received GNP-LLO91–99 equally robust best strategy without complexity cost, making this highly promising development listeriosis.